Tin tức & Cập nhật

Chỉ hiển thị Multimedia

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025 bởi

Treatment with telitacicept reduces proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025

GLP-1 RAs reduce deaths, MACE in at-risk individuals

28 Nov 2025

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.

GLP-1 RAs reduce deaths, MACE in at-risk individuals

28 Nov 2025

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025 bởi

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

27 Nov 2025

In the treatment of patients with chronic kidney disease (CKD) at high risk of progression, a fixed dose combination of balcinrenone and dapagliflozin is well tolerated and results in greater reductions in albuminuria as compared with dapagliflozin alone in reducing albuminuria, according to the phase IIb MIRO-CKD study.

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

27 Nov 2025

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

27 Nov 2025 bởi

The PCSK9 inhibitor evolocumab, when added to background lipid-lowering therapy, helps reduce the risk of major adverse cardiovascular events in patients with atherosclerosis or diabetes who have no history of myocardial infarction (MI) or stroke, according to the randomized VESALIUS-CV trial.

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

27 Nov 2025

Polypill approach shows promise in HFrEF

27 Nov 2025 bởi

A once-daily polypill containing three medications (metoprolol succinate, empagliflozin, and spironolactone) is associated with improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF), according to the POLY-HF trial presented at AHA 2025.

Polypill approach shows promise in HFrEF

27 Nov 2025

Product Highlight - Zolafren

27 Nov 2025

Viên nén 5 mg hoặc 10 mg olanzapin

Product Highlight - Zolafren

27 Nov 2025

Osimertinib linked to cardiac events in NSCLC patients

26 Nov 2025 bởi

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.

Osimertinib linked to cardiac events in NSCLC patients

26 Nov 2025

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

CCBs not associated with variceal haemorrhage in cirrhosis

CCBs not associated with variceal haemorrhage in cirrhosis

Telitacicept reduces proteinuria in adults with IgA nephropathy

Telitacicept reduces proteinuria in adults with IgA nephropathy

GLP-1 RAs reduce deaths, MACE in at-risk individuals

GLP-1 RAs reduce deaths, MACE in at-risk individuals

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

Polypill approach shows promise in HFrEF

Polypill approach shows promise in HFrEF

Product Highlight - Zolafren

Product Highlight - Zolafren

Osimertinib linked to cardiac events in NSCLC patients

Osimertinib linked to cardiac events in NSCLC patients